ALNYLAM PHARMACEUTICALS, INC. Funds and ETFs Alnylam Pharmaceuticals, Inc.
Equities
ALNY
US02043Q1076
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 147.4 USD | -0.33% |
|
-3.21% | -22.99% |
ETFs positioned on Alnylam Pharmaceuticals, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 206 M€ | -.--% | ||
| 0.04% | 1,166 M€ | +0.26% | - | |
| 0.04% | 607 M€ | +0.05% | - | |
| 0.04% | 391 M€ | +9.18% | - | |
| 0.04% | 786 M€ | -.--% | ||
| 0.04% | 23 M€ | -.--% | - | |
| 0.04% | 283 M€ | +19.75% | ||
| 0.04% | 34 M€ | +8.23% | - | |
| 0.03% | 50 M€ | +10.93% | ||
| 0.03% | 205 M€ | -.--% | ||
| 0.03% | 29 M€ | -.--% | - | |
| 0.03% | 322 M€ | +13.88% | - | |
| 0.03% | 306 M€ | +6.45% | - | |
| 0.03% | 39 M€ | +5.99% | - | |
| 0.03% | 1,006 M€ | -.--% | - | |
| 0.03% | 414 M€ | +12.60% | - | |
| 0.02% | 34 M€ | +4.06% | - | |
| 0.02% | 105 M€ | +4.05% | - | |
| 0.02% | 7 M€ | +0.11% | - | |
| 0.02% | 6 M€ | +3.89% | ||
| 0.01% | 17 M€ | +2.74% | - | |
| 0.01% | 54 M€ | +1.07% | - | |
| 0.01% | 8 M€ | +0.48% | - | |
| 0.01% | 2 M€ | +3.16% | - | |
| 0.00% | 756 M€ | +1.40% | - |
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Calendar
10:30am
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
147.4
USD
Average target price
220.4
USD
Spread / Average Target
+49.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.99% | 18.64B | |
| +29.77% | 49.46B | |
| +1.00% | 42.58B | |
| +50.47% | 42.49B | |
| -5.26% | 29.09B | |
| +13.68% | 26.61B | |
| +8.22% | 13.16B | |
| +32.41% | 12.55B | |
| -1.62% | 11.98B | |
| +24.01% | 12.1B |
- Stock Market
- Equities
- ALNY Stock
- Funds and ETFs Alnylam Pharmaceuticals, Inc.
